The EEF1A2 Knockout HeLa Polyclonal Cells product consists of a heterogeneous population of HeLa cells subjected to CRISPR/Cas9-mediated targeted disruption of the EEF1A2 gene. This polyclonal knockout cell pool provides a physiologically diverse loss-of-function model, avoiding the clonal artifacts associated with single-cell-derived lines. It is designed for researchers investigating the canonical and non-canonical roles of the eEF1A2 protein in translation elongation, cytoskeletal organization, and cell survival signaling. The polyclonal nature preserves the genetic variability of the parental HeLa population, enabling robust functional studies in a cancer-relevant background.
HeLa cells are a widely used human cervical adenocarcinoma epithelial cell line, originally derived from a patient positive for human papillomavirus type 18. These adherent cells exhibit rapid proliferation and have become a cornerstone model in cancer biology, virology, and general cell biology. Their well-characterized signaling pathways, including hyperactive PI3K/Akt/mTOR and MYC-driven transcriptional networks, make them particularly suitable for dissecting the molecular functions of oncogenes and tumor suppressors. The integration of an EEF1A2 knockout in this established line offers a direct platform to interrogate the gene’s contribution to malignant phenotypes.
EEF1A2 encodes a translation elongation factor responsible for delivering aminoacyl-tRNAs to the ribosome during peptide chain elongation. Beyond its housekeeping function, eEF1A2 moonlights as an actin-bundling protein and a mediator of Akt-dependent anti-apoptotic signaling. It is regulated by upstream factors such as MYC, AKT1, EGF, IGF-1, and STAT3, and it interacts with ACTB, AKT1, HSP90AA1, MDM2, and 14-3-3 proteins (YWHAZ, YWHAB). Downstream, eEF1A2 promotes the expression of Bcl-xL and Bcl-2 while modulating MDM2 and p53 stability, thereby enhancing cell survival. In the mTOR signaling pathway, EEF1A2 functions coordinately with MTOR, RPS6KB1, EIF4EBP1, AKT1, and PIK3CA to regulate protein synthesis and growth.
In the context of HeLa cells, disruption of EEF1A2 is expected to impair translation elongation and compromise Akt-mediated survival signals, sensitizing cells to apoptotic stimuli and altering cytoskeletal dynamics. Given the HeLa cell line’s origin from cervical adenocarcinoma, this knockout model is particularly relevant for studying the role of eEF1A2 in human papillomavirus-associated oncogenesis and the maintenance of the transformed state. The model allows for the examination of EEF1A2-dependent changes in cell proliferation, migration, and response to chemotherapeutic agents, providing insight into its dual functions in protein synthesis and non-canonical signaling.
This knockout cell population supports a wide range of experimental applications. It is suitable for cancer research, particularly breast, ovarian, hepatocellular, and cervical carcinoma studies, as well as neurobiology and investigations into translation regulation and apoptosis. Representative assays include Western blotting and RT-qPCR for expression analysis, RNA-seq for transcriptomic profiling, co-immunoprecipitation for protein interaction studies, immunofluorescence microscopy for subcellular localization and actin cytoskeleton visualization, flow cytometry with Annexin V for apoptosis quantification, MTT assays for viability assessment, transwell migration and invasion assays, and phospho-Akt signaling analysis. These tools enable detailed mechanistic dissection of EEF1A2 function. For further technical details or to request a quote, please contact Ascent Research.
